

UCSF

UC San Francisco Previously Published Works

Title

Cytochrome P450 Drives a HIF-Regulated Behavioral Response to Reoxygenation by *C. elegans*

Permalink

<https://escholarship.org/uc/item/7mc6k017>

Journal

Science, 341(6145)

ISSN

0036-8075

Authors

K., Dengke
Rothe, Michael
Zheng, Shu
[et al.](#)

Publication Date

2013-08-02

DOI

10.1126/science.1235753

Peer reviewed

Published in final edited form as:

Science. 2013 August 2; 341(6145): 554–558. doi:10.1126/science.1235753.

Cytochrome P450 Drives a HIF-regulated Behavioral Response to Reoxygenation by *C. elegans*

Dengke K. Ma¹, Michael Rothe², Shu Zheng¹, Nikhil Bhatla¹, Corinne L. Pender¹, Ralph Menzel³, and H. Robert Horvitz^{1,*}

¹Howard Hughes Medical Institute, Department of Biology, McGovern Institute for Brain Research, Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA 02139, USA

²Lipidomix GmbH, Robert-Roessle-Str. 10, 13125 Berlin, Germany

³Humboldt-Universität zu Berlin, Department of Biology, Freshwater and Stress Ecology, Spaethstr. 80/81, 12437 Berlin, Germany

Abstract

Oxygen deprivation followed by reoxygenation causes pathological responses in many disorders, including ischemic stroke, heart attacks and reperfusion injury. Key aspects of ischemia-reperfusion can be modeled by a *C. elegans* behavior, the O₂-ON response, which is suppressed by hypoxic preconditioning or inactivation of the O₂-sensing HIF (hypoxia-inducible-factor) hydroxylase EGL-9. From a genetic screen, we found that the cytochrome P450 oxygenase CYP-13A12 acts in response to the EGL-9/HIF-1 pathway to facilitate the O₂-ON response. CYP-13A12 promotes oxidation of polyunsaturated fatty acids into eicosanoids, signaling molecules that can strongly affect inflammatory pain and ischemia-reperfusion injury responses in mammals. We propose that roles of the EGL-9/HIF-1 pathway and cytochrome P450 in controlling responses to anoxia-reoxygenation are evolutionarily conserved.

Ischemia-reperfusion-related disorders, such as strokes and heart attacks, are the most common causes of adult deaths worldwide (1). Blood delivers O₂ and nutrients to target tissues, and ischemia results when the blood supply is interrupted. The restoration of O₂ from blood flow after ischemia, known as reperfusion, can exacerbate tissue damage (2). How organisms prevent ischemia-reperfusion injury is poorly understood. Studies of the nematode *C. elegans* led to discovery of an evolutionarily conserved family of O₂-dependent enzymes (EGL-9 in *C. elegans* and EGLN2 in mammals) that hydroxylate the HIF transcription factor and link hypoxia to HIF-mediated physiological responses (3–7). Exposure to chronic low concentrations of O₂ (hypoxic preconditioning) or direct inhibition of EGLN2 strongly protects mammals from stroke and ischemia-reperfusion injury (2, 8, 9). Similarly, EGL-9 inactivation in *C. elegans* blocks a behavioral response to reoxygenation, the O₂-ON response (characterized by a rapidly increased locomotion speed triggered by reoxygenation after anoxia) (10, 11), which is similar to mammalian tissue responses to ischemia-reperfusion: (i) reoxygenation drives the O₂-ON response and is the major pathological driver of reperfusion injury, (ii) hypoxic preconditioning can suppress both processes, and (iii) the central regulators (EGL-9/HIF) of both processes are evolutionarily conserved. How the EGL-9/HIF-1 and EGLN2/HIF pathways control the O₂-ON response and ischemia-reperfusion injury, respectively, is largely unknown.

*Correspondence to: horvitz@mit.edu.

To seek EGL-9/HIF-1 effectors important in the O₂-ON response, we performed an *egl-9* suppressor screen for mutations that can restore the defective O₂-ON response in *egl-9* mutants (fig. S1A). We identified new alleles of *hif-1* in this screen; because EGL-9 inhibits HIF-1, *hif-1* mutations suppress the effects of *egl-9* mutations (10). We also identified mutations that are not alleles of *hif-1* (Figs. 1A–1C and fig. S1B). *hif-1* mutations recessively suppressed three defects of *egl-9* mutants: the defective O₂-ON response, defects in egg-laying and the ectopic expression of the HIF-1 target gene *cysl-2* (previously called *K10H10.2*) (fig. S1C) (10, 12). By contrast, one mutation, *n5590*, dominantly suppressed the O₂-ON defect but did not suppress the egg-laying defect or the ectopic expression of *cysl-2::GFP* (Figs. 1D, 1E and fig. S2). *n5590* restored the sustained phase (starting at 30s post-reoxygenation) better than it did the initial phase (within 30s post-reoxygenation) (Figs. 1A–1C). *egl-9; hif-1; n5590* triple mutants displayed a normal O₂-ON response, just like the wild type and *egl-9; hif-1* double mutants (fig. S1D). Thus, *n5590* specifically suppresses the *egl-9* defect in the sustained phase of the O₂-ON response.

We genetically mapped *n5590* and identified an M46I missense mutation in the gene *cyp-13A12* by whole-genome sequencing (Fig. 2A, fig. S3A and Table S1A). Decreased wild-type *cyp-13A12* gene dosage in animals heterozygous for a wild-type allele and the splice acceptor null mutation *gk733685*, which truncates the majority of the protein, did not recapitulate the dominant effect of *n5590* (Fig. 2B). *gk733685* homozygous mutants similarly did not recapitulate the effect of *n5590* (Fig. 2C). Thus, *n5590* does not cause a loss of gene function. By contrast, increasing wild-type *cyp-13A12* gene dosage by overexpression restored the sustained phase of the O₂-ON response (Fig. 2D), and RNAi against *cyp-13A12* abolished the effect of *n5590* (Fig. 2E). We conclude that *n5590* is a gain-of-function allele of *cyp-13A12*.

cyp-13A12 encodes a cytochrome P450 oxygenase (CYP). CYPs can oxidize diverse substrates (13–15). The *C. elegans* genome contains 82 CYP genes, at least two of which are polyunsaturated fatty acid (PUFA) oxygenases that generate eicosanoid signaling molecules (fig. S3B) (16, 17). The closest human homolog of CYP-13A12 based on BLASTP scores is CYP3A4 (fig. S4). We aligned the protein sequences of CYP-13A12 and CYP3A4 and found that *n5590* converts methionine 46 to an isoleucine, the residue in the corresponding position of normal human CYP3A4 (fig. S4). Methionines can be oxidized by free radicals, which are produced in the CYP enzymatic cycle, rendering CYPs prone to degradation (18, 19). Using transcriptional and translational GFP-based reporters, we identified the pharyngeal marginal cells as the major site of expression of *cyp-13A12* (fig. S5) and observed that the abundance of CYP-13A12::GFP protein was decreased by prolonged hypoxic preconditioning and also decreased in *egl-9* but not in *egl-9; hif-1* mutants (Fig. 2F and fig. S5). The *n5590* mutation prevented the decrease in CYP-13A12::GFP abundance by hypoxia or *egl-9*. Thus, *n5590* acts, at least in part, by restoring the normal abundance of CYP-13A12, which then promotes the O₂-ON response in *egl-9* mutants.

We tested whether CYP-13A12 was normally required for the O₂-ON response in wild-type animals. The *cyp-13A12* null allele *gk733685* abolished the sustained phase of the O₂-ON response; the initial phase of the O₂-ON response was unaffected (Fig. 3A). A wild-type *cyp-13A12* transgene fully rescued this defect (Fig. 3B). A primary role of CYP-13A12 in the sustained phase of the O₂-ON response explains the incomplete rescue of the defective O₂-ON response of *egl-9* mutants by *n5590* during the initial phase (Fig. 1C). The activity of most and possibly all *C. elegans* CYPs requires EMB-8, a CYP reductase that transfers electrons to CYPs (20). No non-CYP EMB-8 targets are known. *emb-8(hc69)* causes a temperature-sensitive embryonic lethal phenotype. We grew *emb-8(hc69)* mutants at the permissive temperature to the young-adult stage. A shift to the non-permissive temperature simultaneously with *E. coli*-feeding RNAi against *emb-8* nearly abolished the O₂-ON

response (Figs. 3C and 3D) (Both the *hc69* mutation and RNAi against *emb-8* were required to substantially reduce the level of EMB-8 (17).) CYP-13A12 is thus required for the sustained phase of the O₂-ON response, and one or more other CYPs likely act with CYP-13A12 to control both phases of the O₂-ON response.

CYP oxygenases define one of three enzyme families that can convert PUFAs to eicosanoids, signaling molecules that affect inflammatory pain and ischemia-reperfusion responses of mammals (15, 21–23); the other two families, cyclooxygenases and lipoxygenases, do not appear to be present in *C. elegans* (17, 24). To test whether eicosanoids are regulated by EGL-9 and CYP-13A12, we used high-performance liquid chromatography (HPLC) coupled with mass spectrometry (MS) to profile steady-state amounts of 21 endogenous eicosanoid species from cell extracts of wild-type, *egl-9(n586)* and *egl-9(n586); cyp-13A12(n5590)* strains. Only free eicosanoids have potential signaling roles (21, 22, 24), so we focused on free eicosanoids. The *egl-9* mutation caused a markedly decreased overall amount of free eicosanoids, while the total amount of eicosanoid, including both free and membrane-bound fractions, was unaltered (Fig. 4A and fig. S6). Among the eicosanoids profiled, 17,18-DiHEQ (17,18-diolhydroxyeicosatetraenoic acid) was the most abundant species (fig. S6B). 17,18-DiHEQ is the catabolic hydrolase product of 17,18-EEQ (17,18-epoxyeicosatetraenoic acid), an epoxide active in eicosanoid signaling (25). Free cytosolic 17,18-EEQ and 19-hydroxyeicosatetraenoic acid (19-HETE) were present in the wild type but undetectable in *egl-9* mutants (Figs. 4C–4F). *egl-9(n586); cyp-13A12(n5590)* mutants exhibited partially restored free overall eicosanoid levels as well as restored levels of 17,18-EEQ and 19-HETE (Figs. 4A–4F and fig. S6B). Thus, both EGL-9 and CYP-13A12 regulate amounts of free cytosolic eicosanoids.

We tested whether the O₂-ON response requires PUFAs, which are CYP substrates and eicosanoid precursors. PUFA-deficient *fat-2* and *fat-3* mutants (26) exhibited a complete lack of the O₂-ON response, although the acceleration in response to anoxia preceding the O₂-ON response was normal (Fig. 4G and figs. S7A–S7C). The defective O₂-ON response of *fat-2* mutants was restored by feeding animals the C20 PUFA arachidonic acid (Fig. 4H) but not oleate, a C18 monounsaturated fatty acid that is processed by FAT-2 to generate C20 PUFAs (fig. S7D). These results demonstrate an essential role of PUFAs for the O₂-ON response.

We suggest a model in which CYPs, which are strictly O₂-dependent (27, 28), generate eicosanoids to drive the O₂-ON response (Figs. 4I and fig. S8). In this model, EGL-9 acts as a chronic O₂-sensor, so that during hypoxic preconditioning, the O₂-dependent activity of EGL-9 is inhibited, HIF-1 is activated and unknown HIF-1 up-regulated targets decrease CYP protein abundance. The low abundance of CYPs defines the hypoxic preconditioned state. Without hypoxic preconditioning, CYPs generate eicosanoids, which drive the O₂-ON response. By contrast, with hypoxic preconditioning or in *egl-9* mutants, the CYP amounts are insufficient to generate eicosanoids and the O₂-ON response is not triggered. Neither C20 PUFAs nor overexpression of CYP-29A3 restored the defective O₂-ON response of *egl-9* mutants (figs. S9 and S10), indicating that this defect is unlikely caused by a general deficiency in C20 PUFAs or CYPs. Since the O₂-ON response requires EMB-8, a general CYP reductase, but only the sustained phase requires CYP-13A12, we propose that CYP-13A12 and other CYPs act as acute O₂ sensors and produce eicosanoids, which are short-lived and act locally (22) during reoxygenation to signal nearby sensory circuits that drive the O₂-ON response.

In humans, a low uptake of PUFAs or an imbalanced ratio of ω 3/ ω 6 PUFAs is associated with elevated risk of stroke, cardiovascular disease and cancer (21, 23, 29, 30). Cytochrome P450s and eicosanoid production also have been implicated in mammalian ischemia-

reperfusion (15, 21). Nonetheless, the causal relationships among and mechanisms relating O₂ and PUFA homeostasis, CYP and PUFA-mediated cell signaling and organismal susceptibility to oxidative disorders are poorly understood. We identify a novel pathway in which EGL-9/HIF-1 regulates CYP-eicosanoid signaling, demonstrate that PUFAs confer a rapid response to reoxygenation via CYP-generated eicosanoids and provide direct causal links among CYPs, PUFA-derived eicosanoids, and an animal behavioral response to reoxygenation. As molecular mechanisms of O₂ and PUFA homeostasis are fundamentally similar and evolutionarily conserved between nematodes and mammals (7, 11, 26), we suggest that the *C. elegans* O₂-ON response is analogous to the mammalian tissue/cellular response to ischemia-reperfusion injury and that the principle of CYP-mediated regulation and the molecular pathway including EGL-9/HIF-1 and CYPs in controlling responses to anoxia-reoxygenation are evolutionarily conserved.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank C. Bargmann, A. Fire, A. Hart, Y. Iino, J. Powell-Coffman and C. Rongo for reagents; the *Caenorhabditis* Genetics Center and the Million Mutation Project for strains. H.R.H. is an Investigator of the Howard Hughes Medical Institute and the David H. Koch Professor of Biology at MIT. Supported by NIH grant GM24663 (H.R.H.), German Research Foundation grant ME2056/3-1 (R.M.), NSF Graduate Research Fellowship (N.B.), MIT Undergraduate Research Opportunities Program (S.Z.) and a Helen Hay Whitney Foundation postdoctoral fellowship (D.K.M.).

References and Notes

1. Go AS, et al. *Circulation*. Dec 12.2012
2. Eltzschig HK, Eckle T. *Nat Med*. 2011; 17:1391. [PubMed: 22064429]
3. Epstein AC, et al. *Cell*. Oct 5.2001 107:43. [PubMed: 11595184]
4. Kaelin WG Jr, Ratcliffe PJ. *Mol Cell*. May 23.2008 30:393. [PubMed: 18498744]
5. Trent C, Tsung N, Horvitz HR. *Genetics*. Aug.1983 104:619. [PubMed: 11813735]
6. Semenza GL. *Cell*. Feb 3.2012 148:399. [PubMed: 22304911]
7. Powell-Coffman JA. *Trends Endocrinol Metab*. Jul.2010 21:435. [PubMed: 20335046]
8. Semenza GL. *Biochim Biophys Acta*. Jul.2011 1813:1263. [PubMed: 20732359]
9. Aragonés J, et al. *Nat Genet*. Feb.2008 40:170. [PubMed: 18176562]
10. Ma DK, Vozdek R, Bhatla N, Horvitz HR. *Neuron*. Mar 8.2012 73:925. [PubMed: 22405203]
11. Ma DK, Ringstad N. *Front Biol*. Jun.2012 7:246.
12. Budde MW, Roth MB. *Genetics*. Oct.2011 189:521. [PubMed: 21840852]
13. Nelson DR, et al. *Pharmacogenetics*. Feb.1996 6:1. [PubMed: 8845856]
14. Gotoh O. *Mol Biol Evol*. Nov.1998 15:1447. [PubMed: 12572608]
15. Gottlieb RA. *Arch Biochem Biophys*. Dec 15.2003 420:262. [PubMed: 14654065]
16. Kosel M, et al. *Biochem J*. May 1.2011 435:689. [PubMed: 21309752]
17. Kulas J, Schmidt C, Rothe M, Schunck WH, Menzel R. *Arch Biochem Biophys*. Apr 1.2008 472:65. [PubMed: 18282462]
18. Berlett BS, Stadtman ER. *J Biol Chem*. Aug 15.1997 272:20313. [PubMed: 9252331]
19. Zangar RC, Davydov DR, Verma S. *Toxicol Appl Pharmacol*. Sep 15.2004 199:316. [PubMed: 15364547]
20. Rappleye CA, Tagawa A, Le Bot N, Ahringer J, Aroian RV. *BMC developmental biology*. Oct 3.2003 3:3. [PubMed: 12697064]
21. Szefel J, et al. *Curr Mol Med*. Feb.2011 11:13. [PubMed: 21189121]
22. Wymann MP, Schneider R. *Nat Rev Mol Cell Biol*. Feb.2008 9:162. [PubMed: 18216772]

23. Chapkin RS, Kim W, Lupton JR, McMurray DN. Prostaglandins Leukot Essent Fatty Acids. Aug-Sep;2009 81:187. [PubMed: 19502020]
24. Panigrahy D, Kaipainen A, Greene ER, Huang S. Cancer Metastasis Rev. Dec.2010 29:723. [PubMed: 20941528]
25. Arnold C, et al. J Biol Chem. Oct 22.2010 285:32720. [PubMed: 20732876]
26. Watts JL. Trends Endocrinol Metab. Mar.2009 20:58. [PubMed: 19181539]
27. Harder DR, et al. Circ Res. Jul.1996 79:54. [PubMed: 8925569]
28. Ward JP. Biochim Biophys Acta. Jan.2008 1777:1. [PubMed: 18036551]
29. Gerber M. Br J Nutr. Jun.2012 107(Suppl 2):S228. [PubMed: 22591896]
30. Mozaffarian D, Wu JH. J Am Coll Cardiol. Nov 8.2011 58:2047. [PubMed: 22051327]




Fig. 1. *n5590* suppresses the defect of *egl-9* mutants in the O₂-ON response

(A) Speed graph of wild-type animals, showing a normal O₂-ON response. Average speed values \pm 2 SEMs (blue) of animals ($n > 50$) are shown with step changes of O₂ between 20% and 0% at the indicated times. The mean speed within 0–120 s after O₂ restoration is increased compared with that before O₂ restoration ($p < 0.01$, one-sided unpaired t-test). The dashed green line indicates the approximate boundary (30s post-reoxygenation) between the initial and sustained phases of the O₂-ON response. (B) Speed graph of *egl-9(n586)* mutants, showing a defective O₂-ON response. (C) Speed graph of *egl-9(n586); cyp-13A12(n5590)* mutants, showing a restored O₂-ON response mainly in the sustained phase (right of the dashed green line). The mean speed within 30–120 s after O₂ restoration was significantly higher than that of *egl-9(n586)* mutants ($p < 0.01$). (D) Speed graph of *egl-9(n586); cyp-13A12(n5590)/+* mutants, showing a restored O₂-ON response in the sustained phase. (E) *hif-1* but not *cyp-13A12(n5590)* suppressed the expression of *cysl-2::GFP* by *egl-9(n586)* mutants. GFP fluorescence micrographs of 5–7 worms aligned side by side carrying the transgene *nls470* [*P_{cysl-2}::GFP*] are shown. Scale bar, 50 µm.




Fig. 2. *n5590* is a gain-of-function allele of *cyp-13A12*

(A) Genetic mapping positioned *n5590* between the SNPs *pkP3075* and *uCE3-1426*. Solid grey lines indicate genomic regions for which recombinants exhibited a defective O2-ON response, thus excluding *n5590* from those regions. The locations of *n5590* and *gk733685* are indicated in the gene diagram of *cyp-13A12*. (B) Speed graph of *egl-9(n586); cyp-13A12(gk733685)/+* animals, showing a defective O2-ON response. (C) Speed graph of *egl-9(n586); cyp-13A12(gk733685)* mutants, showing a defective O2-ON response. (D) Speed graph of *egl-9(n586); nEx[cyp-13A12(+)]* animals, showing a restored O2-ON response in the sustained phase (right of the dashed green line). (E) Speed graph of *egl-9(n586); cyp-13A12(n5590); cyp-13A12(RNAi)* animals, showing a suppressed O2-ON response. (F) Fractions of animals expressing CYP-13A12::GFP or CYP-13A12(*n5590*)::GFP (* $p < 0.01$, two-way ANOVA with Bonferroni's test, $n=4$).




Fig. 3. Requirement of CYP-13A12 for a normal O₂-ON response

(A) Speed graph of *cyp-13A12(gk733685)* loss-of-function mutants, showing an O₂-ON response with a normal initial phase but a diminished sustained phase (left and right, respectively, of the dashed green line). (B) Speed graph of *cyp-13A12(gk733685)* mutants with a rescuing wild-type *cyp-13A12* transgene, showing the O₂-ON response with a normal initial phase and sustained phase. The mean speed within 30–120 s after O₂ restoration was higher than that of *cyp-13A12(gk733685)* mutants ($p < 0.01$, one-sided unpaired t-test, $n > 50$). (C) Speed graph of *emb-8(hc69)* mutants growing at the permissive temperature of 15°C with simultaneous *E. coli* feeding RNAi against *emb-8*, showing a normal O₂-ON response. (D) Speed graph of *emb-8(hc69)* mutants growing post-embryonically at the restrictive temperature of 25°C with simultaneous *E. coli* feeding-RNAi against *emb-8*, showing a reduced O₂-ON response.




Fig. 4. Modulation of eicosanoid concentrations by EGL-9 and CYP-13A12

(A) Overall levels of free eicosanoids, calculated by adding the values of the profiled 21 eicosanoids in the wild type and *egl-9(n586)* and *egl-9(n586); cyp-13A12(n5590)* strains. (B) Schematic illustrating the conversion of arachidonic acid (AA, 20:4n-6) to 19-HETE and of EPA (20:5n-3) to 17,18-EEQ by CYPs. (C) Quantification of 19-HETE and 17,18-EEQ concentrations in the wild type and *egl-9(n586); cyp-13A12(n5590)* and *egl-9(n586)* mutant strains. Amounts of free (membrane unbound) forms of 17,18-EEQ and 19-HETE from extracts of age-synchronized young adult hermaphrodites are shown. $p < 0.01$, one-way ANOVA post hoc test, $n = 3$. Error bars are SEMs. (D–F) Representative HPLC-MS traces indicating free 17,18-EEQ levels based on the spectrograms of three MS samples: (D) wild type, (E) *egl-9(n586)*, and (F) *egl-9(n586); cyp-13A12(n5590)*. Peaks of 17,18-EEQ at its transition m/z (mass-to-charge ratio) were measured and extracted (MassHunter). The x-axis shows the retention time (minutes); the y-axis shows the abundance (counts), with specific integral values over individual peaks indicated above each peak. (G) Speed graph of *fat-2* mutants, showing a defective O₂-ON response. Animals were supplemented with the solvents used in (H) as a control. (H) Speed graph of *fat-2* mutants, showing the O₂-ON response rescued by C20 PUFA (AA) supplementation. (I–J) Model of how EGL-9 and CYPs control the O₂-ON response under (I) normoxic conditions and (J) conditions of hypoxic preconditioning or in *egl-9* mutants (see text for details). The light blue indicates low protein activity, low amounts of eicosanoids or a defective O₂-ON response.